Gou Hongfeng, Chen Xinchuan, Hou Mei, Yang Yu
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R.China.
Zhongguo Fei Ai Za Zhi. 2007 Apr 20;10(2):141-3. doi: 10.3779/j.issn.1009-3419.2007.02.14.
Cisplatin-based chemotherapy is the standard regimens in the treatment of advanced non-small cell lung cancer (NSCLC). The aim of this trial is to evaluate the efficacy and toxicity of paclitaxel or gemcitabine combined with cispltin for patients with advanced NSCLC.
Seventy-seven advanced NSCLC patients were randomly divided into 2 groups, 39 in TP group and 38 in GP group. TP group: paclitaxel 135 mg/m², on day 1; cisplatin 30 mg/m², on days 1-3. GP group: gemcitabine 1000 mg/m², on days 1, 8; cisplatin 30 mg/m², on days 1-3.
Patients' characteristics were similar between the two groups. The overall response rate was 46.2% in the TP group and 42.1% in the GP group. There was no statistically significant difference in response rate between the two groups (P > 0.05). The major cytotoxicity was leukopenia in the TP group and thrombocytopenia in the GP group.
Both TP and GP regimens are effective for advanced NSCLC and have no significant difference. The side effects of the two regimens are different but all adverse reactions are tolerable.
以顺铂为基础的化疗是晚期非小细胞肺癌（NSCLC）治疗的标准方案。本试验的目的是评估紫杉醇或吉西他滨联合顺铂治疗晚期NSCLC患者的疗效和毒性。
77例晚期NSCLC患者随机分为2组，TP组39例，GP组38例。TP组：紫杉醇135mg/m²，第1天；顺铂30mg/m²，第1 - 3天。GP组：吉西他滨1000mg/m²，第1、8天；顺铂30mg/m²，第1 - 3天。
两组患者特征相似。TP组总有效率为46.2%，GP组为42.1%。两组有效率差异无统计学意义（P>0.05）。主要细胞毒性反应在TP组为白细胞减少，在GP组为血小板减少。
TP方案和GP方案对晚期NSCLC均有效且无显著差异。两种方案的副作用不同，但所有不良反应均可耐受。
